| Name | tissue plasminogen activator |
|---|---|
| Synonyms | Alteplase; Neonatal thrombolytic agent alpha form; PLAT; PLAT protein; Reteplase; T PA; TPA; TPA protein… |
| Name | warfarin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20212195 | Prabhakaran S, Rivolta J, Vieira JR, Rincon F, Stillman J, Marshall RS, Chong JY: Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. Arch Neurol. 2010 Mar 8. |
12(0,0,2,2) | Details |
| 20189089 | Hinchey JA, Shephard T, Tonn ST, Ruthazer R, Hermann RC, Selker HP, Kent DM: The Stroke Practice Improvement Network: a quasiexperimental trial of a multifaceted intervention to improve quality. J Stroke Cerebrovasc Dis. 2010 Mar;19(2):130-7. OBJECTIVE: The aim of this project was to determine whether a tailored multifaceted intervention aimed at site-specific barriers is more effective than audit feedback alone for improving adherence to inhospital stroke performance measures (PMs): door to needle time of less than 1 hour for tissue plasminogen activator, dysphagia screening, deep venous thrombosis prophylaxis, and warfarin treatment for atrial fibrillation. |
7(0,0,1,2) | Details |
| 19713669 | Yamamoto Y, Suzuki M, Kawada Y, Kamogawa K, Okamoto K, Okuda B: [Pulseless arrest in an elderly patient treated with intravenous tissue plasminogen activator for cardioembolic ischemic stroke]. Nippon Ronen Igakkai Zasshi. 2009 Jul;46(4):352-7. She had taken warfarin for over 10 years, but her condition was not well controlled on admission. |
2(0,0,0,2) | Details |
| 19202954 | Hart RG: What's new in stroke? The top 10 studies of 2006-2008. Pol Arch Med Wewn. 2008 Dec;118(12):747-55. Intravenous tissue plasminogen activator is of overall benefit to selected patients when given 3 to 4.5 hours after ischemic stroke onset (ECASS III). Adjusted-dose warfarin is far superior to and is relatively safe for very old people with atrial fibrillation (BAFTA). |
1(0,0,0,1) | Details |
| 19876861 | Gresham C, Levine M, Ruha AM: Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose. J Med Toxicol. 2009 Dec;5(4):242-9. He previously had an inferior vena cava filter placed, and had received tissue plasminogen activator (tPA) for a cerebrovascular accident. |
1(0,0,0,1) | Details |
| 18468545 | Donnan GA, Fisher M, Macleod M, Davis SM: Stroke. . Lancet. 2008 May 10;371(9624):1612-23. For patients with acute stroke, management in a stroke care unit, intravenous tissue plasminogen activator within 3 h or within 48 h of stroke onset, and decompressive surgery for supratentorial malignant hemispheric cerebral infarction are interventions of proven benefit; several other interventions are being assessed. Proven secondary prevention strategies are warfarin for patients with atrial fibrillation, endarterectomy for symptomatic carotid stenosis, antiplatelet agents, and reduction. |
1(0,0,0,1) | Details |
| 20156003 | Glick JA, Brophy GM: Prevention and treatment of cardioembolic stroke: a case study. Consult Pharm. 2009 Dec;24(12):903-9. Secondary prevention of stroke for this patient included treatment of hypertension, diabetes, and hypercholesterolemia as well as initiation of warfarin. Blood pressure (BP) goals during the first 24 hours depend on eligibility for tissue plasminogen activator (tPA). |
1(0,0,0,1) | Details |
| 19280874 | Chang YJ, Ryu SJ, Chen JR, Hu HH, Yip PK, Chiu TF: [Guidelines for the general management of patients with acute ischemic stroke]. Acta Neurol Taiwan. 2008 Dec;17(4):275-94. Intravenous recombinant tissue plasminogen activator treatment within three hours is effective in reducing disability for patients with acute ischemic stroke. Dose-adjusted warfarin (INR range of 2.0-3.0) is recommended for ischemic stroke patients with persistent or paroxysmal atrial fibrillation to prevent secondary embolism. |
1(0,0,0,1) | Details |
| 19092656 | Nielsen VG, Kirklin JK, Holman WL, Steenwyk BL: Clot lifespan model analysis of the effects of warfarin on thrombus growth and fibrinolysis: role of contact protein and tissue factor initiation. ASAIO J. 2009 Jan-Feb;55(1):33-40. Normal subject or patient plasma with INR values between 1.8 and 9.6 were exposed to TF or celite and tissue-type plasminogen activator (tPA). |
1(0,0,0,1) | Details |
| 18625852 | Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC: Anticoagulation after cardioembolic stroke: to bridge or not to bridge? . Arch Neurol. 2008 Sep;65(9):1169-73. Epub 2008 Jul 14. Patients were grouped by treatment: no treatment, only, followed by warfarin sodium, intravenous in the acute phase followed by warfarin bridging), and full-dose combined with warfarin bridging). |
0(0,0,0,0) | Details |